Disease Activity May Not Affect the Prognosis of Coexisting Thyroid Cancer in Acromegalic Patients.


Journal

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
ISSN: 1439-3646
Titre abrégé: Exp Clin Endocrinol Diabetes
Pays: Germany
ID NLM: 9505926

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 12 6 2019
medline: 1 6 2021
entrez: 12 6 2019
Statut: ppublish

Résumé

Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1. Differentiated thyroid cancer (DTC) is reported to be one of the most frequent malignancies associated with acromegaly. But there is no data about the clinical course of DTC in acromegalic patients. In this study, we evaluated the course of DTC in 14 acromegalic patients retrospectively. Fourteen papillary thyroid cancer patients without acromegaly, who were matched with the acromegalic patient group for age, gender and properties of thyroid cancer, were investigated as the control group. We identified no change in the course and treatment responses of DTC in association with the acromegaly activity, gender, age and disease duration, and all patients were found to be in remission for DTC at the time of investigation. Retrospective analysis of this cohort suggests that the activity of acromegaly may not affect the treatment responses and prognosis of coexisting DTC.

Identifiants

pubmed: 31185505
doi: 10.1055/a-0915-1982
doi:

Substances chimiques

IGF1 protein, human 0
Human Growth Hormone 12629-01-5
Insulin-Like Growth Factor I 67763-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

567-572

Informations de copyright

© Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

The authors declare that they have no conflict of interest.

Auteurs

Nurdan Gul (N)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey.

Ozlem Soyluk (O)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey.

Sema Ciftci Dogansen (SC)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey.

Neslihan Kurtulmus (N)

Maslak Hospital, Division of Endocrinology and Metabolism, Acibadem University, Maslak, Istanbul, Turkey.

Sema Yarman (S)

Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH